Veracyte (FRA:12V) Total Liabilities : €89.2 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte Total Liabilities?

Veracyte's Total Liabilities for the quarter that ended in Sep. 2024 was €89.2 Mil.

Veracyte's quarterly Total Liabilities increased from Mar. 2024 (€74.91 Mil) to Jun. 2024 (€94.58 Mil) but then declined from Jun. 2024 (€94.58 Mil) to Sep. 2024 (€89.18 Mil).

Veracyte's annual Total Liabilities declined from Dec. 2021 (€80.81 Mil) to Dec. 2022 (€76.67 Mil) and declined from Dec. 2022 (€76.67 Mil) to Dec. 2023 (€64.93 Mil).

Veracyte Total Liabilities Historical Data

The historical data trend for Veracyte's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Total Liabilities Chart

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

32.18

29.54

80.81

76.67

64.93

Veracyte Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															66.42	64.93	74.91	94.58	89.18

Veracyte Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Veracyte's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	56.158	+	(6.9	+	1.196
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.673	+	0)
	=	64.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1022.369	-	957.442
	=	64.9

Veracyte's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	63.352	+	(11.172	+	13.332
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.324	+	0)
	=	89.2

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	1148.794	-	1059.614
	=	89.2

Veracyte Total Liabilities Related Terms

Thank you for viewing the detailed overview of Veracyte's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VCYT:USA 12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Veracyte Headlines

No Headlines